Lipigon Pharmaceuticals (Sweden) Buy Hold or Sell Recommendation
| LPGO Stock | SEK 0.19 0.01 5.00% |
Assuming the 90 days trading horizon and your above-average risk tolerance, our recommendation regarding Lipigon Pharmaceuticals AB is 'Strong Sell'. A buy or sell recommendation is an automated directive regarding whether to purchase or sell Lipigon Pharmaceuticals AB given historical horizon and risk tolerance. When we issue a 'buy' or 'sell' recommendation for Lipigon Pharmaceuticals AB, the advice is generated through an automated system that utilizes algorithms and statistical models.
Check out Lipigon Pharmaceuticals Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments, please use the Instant Ratings tool. Note, we conduct extensive research on individual companies such as Lipigon and provide practical buy, sell, or hold advice based on investors' constraints. Lipigon Pharmaceuticals AB. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.
Lipigon |
Execute Lipigon Pharmaceuticals Buy or Sell Advice
The Lipigon recommendation should be used to complement the buy-or-sell advice compiled from the current analysts' consensus on Lipigon Pharmaceuticals AB. Macroaxis does not own or have any residual interests in Lipigon Pharmaceuticals AB or other equities on which the buy-or-sell advice is provided. Please provide your input below to execute Lipigon Pharmaceuticals' advice using the current market data and latest reported fundamentals.
Time Horizon
Risk Tolerance
 |  |
Strong Sell
Market Performance | Very Weak | Details | |
Volatility | Out of control | Details | |
Hype Condition | Stale | Details | |
Current Valuation | Overvalued | Details | |
Odds Of Distress | Very High | Details | |
Economic Sensitivity | Moves indifferently to market moves | Details | |
Analyst Consensus | Not Available | Details | |
Reporting Quality (M-Score) | Inapplicable | Details |
Lipigon Pharmaceuticals Trading Alerts and Improvement Suggestions
| Lipigon Pharmaceuticals generated a negative expected return over the last 90 days | |
| Lipigon Pharmaceuticals has high historical volatility and very poor performance | |
| Lipigon Pharmaceuticals has some characteristics of a very speculative penny stock | |
| Lipigon Pharmaceuticals has a very high chance of going through financial distress in the upcoming years | |
| The company reported the revenue of 3.18 M. Net Loss for the year was (41.11 M) with loss before overhead, payroll, taxes, and interest of (36.04 M). | |
| Lipigon Pharmaceuticals AB has accumulated about 58.95 M in cash with (35.3 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 6.06, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Roughly 38.0% of the company outstanding shares are owned by corporate insiders |
Lipigon Pharmaceuticals Returns Distribution Density
The distribution of Lipigon Pharmaceuticals' historical returns is an attempt to chart the uncertainty of Lipigon Pharmaceuticals' future price movements. The chart of the probability distribution of Lipigon Pharmaceuticals daily returns describes the distribution of returns around its average expected value. We use Lipigon Pharmaceuticals AB price's Value At Risk and its Upside Potential as a relative measure of the distribution. The graph of the distribution of Lipigon Pharmaceuticals returns is essential to provide solid investment advice for Lipigon Pharmaceuticals.
| Mean Return | -0.02 | Value At Risk | -7.69 | Potential Upside | 16.67 | Standard Deviation | 7.65 |
Return Density |
| Distribution |
Investment risk management requires an estimate of the probability of extreme price changes. Therefore, the correct representation of the distribution of Lipigon Pharmaceuticals historical returns presented in an easy-to-digest graphical form helps investors and money managers understand the risk-reward trade-off of different investement strategies.
Lipigon Pharmaceuticals Greeks
Most traded equities are subject to two types of risk - systematic (i.e., market) and unsystematic (i.e., nonmarket or company-specific) risk. Unsystematic risk is the risk that events specific to Lipigon Pharmaceuticals or Healthcare sector will adversely affect the stock's price. This type of risk can be diversified away by owning several different stocks in different industries whose stock prices have shown a small correlation to each other. On the other hand, systematic risk is the risk that Lipigon Pharmaceuticals' price will be affected by overall stock market movements and cannot be diversified away. So, no matter how many positions you have, you cannot eliminate market risk. However, you can measure a Lipigon stock's historical response to market movements and buy it if you are comfortable with its volatility direction. Beta and standard deviation are two commonly used measures to help you make the right decision.
α | Alpha over Dow Jones | -0.0089 | |
β | Beta against Dow Jones | -0.19 | |
σ | Overall volatility | 7.69 | |
Ir | Information ratio | -0.02 |
Lipigon Pharmaceuticals Volatility Alert
Lipigon Pharmaceuticals AB is displaying above-average volatility over the selected time horizon. Lipigon Pharmaceuticals AB is a potential penny stock. Although Lipigon Pharmaceuticals may be in fact a good instrument to invest, many penny stocks are speculative in nature and are subject to artificial price hype. Please make sure you totally understand the upside potential and downside risk of investing in Lipigon Pharmaceuticals AB. We encourage investors to look for signals such as email spams, message board hypes, claims of breakthroughs, volume upswings, sudden news releases, promotions that are not reported, or demotions released before SEC filings. Please also check biographies and work history of current and past company officers before investing in high volatility instruments, penny stocks, or equities with microcap classification. You can indeed make money on Lipigon instrument if you perfectly time your entry and exit. However, remember that penny stocks that have been the subject of artificial hype usually unable to maintain their increased share price for more than just a few days. The price of a promoted high volatility instrument will almost always revert back. The only way to increase shareholder value is through legitimate performance backed up by solid fundamentals.Lipigon Pharmaceuticals Fundamentals Vs Peers
Comparing Lipigon Pharmaceuticals' fundamentals to the average values of its peers is one of the most widely used and accepted methods of equity analyses. It helps to analyze Lipigon Pharmaceuticals' direct or indirect competition across all of the common fundamentals between Lipigon Pharmaceuticals and the related equities. This way, we can detect undervalued stocks with similar characteristics as Lipigon Pharmaceuticals or determine the stocks which would be an excellent addition to an existing portfolio. Peer analysis of Lipigon Pharmaceuticals' fundamental indicators could also be used in its relative valuation, which is a method of valuing Lipigon Pharmaceuticals by comparing valuation metrics with those of similar companies.
| Better Than Average | Worse Than Average | Compare Lipigon Pharmaceuticals to competition |
| Fundamentals | Lipigon Pharmaceuticals | Peer Average |
| Return On Equity | -1.7 | -0.31 |
| Return On Asset | -0.94 | -0.14 |
| Operating Margin | (338.33) % | (5.51) % |
| Current Valuation | 5.58 M | 16.62 B |
| Shares Outstanding | 20.24 M | 571.82 M |
| Shares Owned By Insiders | 38.47 % | 10.09 % |
| Shares Owned By Institutions | 12.51 % | 39.21 % |
| Price To Book | 1.62 X | 9.51 X |
| Price To Sales | 147.83 X | 11.42 X |
| Revenue | 3.18 M | 9.43 B |
| Gross Profit | (36.04 M) | 27.38 B |
| EBITDA | (41.09 M) | 3.9 B |
| Net Income | (41.11 M) | 570.98 M |
| Cash And Equivalents | 58.95 M | 2.7 B |
| Cash Per Share | 6.06 X | 5.01 X |
| Current Ratio | 23.62 X | 2.16 X |
| Book Value Per Share | 0.65 X | 1.93 K |
| Cash Flow From Operations | (35.3 M) | 971.22 M |
| Earnings Per Share | (4.65) X | 3.12 X |
| Target Price | 5.4 | |
| Number Of Employees | 7 | 18.84 K |
| Market Capitalization | 25.81 M | 19.03 B |
| Total Asset | 29.43 M | 29.47 B |
| Z Score | -3.3 | 8.72 |
| Net Asset | 29.43 M |
Lipigon Pharmaceuticals Market Momentum
Traders often use several daily momentume indicators to supplement a more traditional technical analysis when analyzing securities such as Lipigon . With many different options, investors must choose the best indicators for them and familiarize themselves with how they work. We suggest combining traditional momentum indicators with more near-term forms of technical analysis such as Accumulation Distribution or Daily Balance Of Power. With their quantitative nature, daily value technical indicators can also be incorporated into your automated trading systems.
| Accumulation Distribution | 11702.95 | |||
| Daily Balance Of Power | (1.00) | |||
| Rate Of Daily Change | 0.95 | |||
| Day Median Price | 0.19 | |||
| Day Typical Price | 0.19 | |||
| Period Momentum Indicator | (0.01) |
About Lipigon Pharmaceuticals Buy or Sell Advice
When is the right time to buy or sell Lipigon Pharmaceuticals AB? Buying financial instruments such as Lipigon Stock isn't very hard. However, what challenging for most investors is doing it at the right time to beat the market. Proper market timing is something most people cannot do without sophisticated tools, which help to isolate the right opportunities. Macroaxis provides hands-on modules to deliver winning trades and diversify your portfolios on a daily basis. Most of our advising modules are very easy to use and apply.
Please read more on our stock advisor page.
Use Investing Ideas to Build Portfolios
In addition to having Lipigon Pharmaceuticals in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Money Funds Thematic Idea Now
Money Funds
Funds or Etfs that invest most if their asset in companies from financial sector such as commercial banks, insurance companies, investment funds, and real estate. The Money Funds theme has 32 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Money Funds Theme or any other thematic opportunities.
| View All Next | Launch |
Additional Tools for Lipigon Stock Analysis
When running Lipigon Pharmaceuticals' price analysis, check to measure Lipigon Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Lipigon Pharmaceuticals is operating at the current time. Most of Lipigon Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Lipigon Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Lipigon Pharmaceuticals' price. Additionally, you may evaluate how the addition of Lipigon Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.